Access to Orphan Drugs in Turkey
Jan 05, 2016
Gülce Belgin and Donald Macarthur explore the options available for companies to meet the needs of the rare disease population in Turkey.
Though Turkey remains outside the European Union and pharmaceutical cost containment features strongly, patients had access with reimbursement to 73% (62 of 85) of orphan drugs approved in the EU in 2015, a higher proportion than in some EU member states. Just 27% (23) of these available drugs were subject to Turkish marketing authorizations, however.
More:Access to Orphan Drugs in Turkey | Pharmaceutical Executive
